The rise of AMR in pathogenic bacteria poses serious challenges to the control and management of infectious diseases.

Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...

Discover what the next wave of AI-assisted drug discovery looks like and how it can help biotech - the AI and physics combo.

Isomorphic Labs, the London-based, drug discovery–focused spinout of Google AI R&D division DeepMind, today announced that it’s entered into strategic partnerships with two pharmaceutical giants, Eli ...

TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...

In developing drugs using a platform that joins physics with machine learning, Schrödinger sees more than a passing resemblance to the studio whose Toy Story and other computer-generated movies ...

This process is costly, time-consuming, and has a low success rate. KAIST researchers have developed an AI model that, using only information about the target protein, can design optimal drug ...

The primary causes of disability and mortality in the US are chronic diseases such as cancer, neurodegenerative disorders, cardiovascular disease, obesity, arthritis, and diabetes. The increase in ...

Ola Engkvist is the Executive Director and Head of Molecular AI in Discovery Sciences within R&D at AstraZeneca (headquartered in Cambridge, UK). His team harnesses advanced computational technologies ...

As soon as pharmaceutical companies recognized the potential of artificial intelligence tools for drug discovery, they rushed in with big money. After all, traditional drug discovery methods are ...